Introduction 
Gastric cancer, TG, gastric cancer
GASTRIC CANCER, DISEASE, GASTRIC CANCER
Gastric cancer is the third leading cause of cancer-related mortality worldwide.Although both DG and TG are safe to perform, previous studies exposed several differences and concerns regarding their associated surgical and oncological outcomes.However, no prospective studies compared outcomes after neoadjuvant chemotherapy and few assessed lymph node retrieval or quality of life, of which none in Western populations. Furthermore, there is heterogeneity among studies, most studies were retrospective and did not address the surgeon’s experience, and not all studies reported follow-up. Moreover, mainly Eastern populations were investigated, who differ from Western patients in disease stage, age, comorbidities, and BMI. Therefore, the aim of the present study was to determine the role of DG and TG for Western gastric cancer patients, in particular after neoadjuvant chemotherapy, by comparing surgical and oncological outcomes including survival and quality of life after distal versus total D2-gastrectomy in the multicenter LOGICA-cohort.